Citations

Clear

9383 citation(s) found for "Thomas, PS".

Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
O’Rourke, Jacqueline G., Meera, Pratap , Muhammad, A.K.M. Ghulam, Grant, Sharday, Simpkinson, Megan, Bell, Shaughn , Carmona, Sharon, Ornelas, Loren, Sahabian, Anais , Petrucelli, Leonard , Baughn, Michael W. , Ravits, John , Harms, Matthew B. , Rigo, Frank , Bennett, C. Frank , Otis, Thomas S. , Svendsen, Clive N. , Baloh, Robert H. , Sareen, Dhruv , Gendron, Tania F.

Mayo Clinic

Science Translational Medicine | October 23, 2013 | Volume: 5 | Issue: 208 | Pages: No page available

10.1126/scitranslmed.3007529 | PMID 24154603 Get It

Antisense oligonucleotides can correct disease-specific phenotypes in cultured motor neurons differentiated from iPSCs derived from ALS patients with a C9ORF72 repeat expansion.
Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma
Marri, Preethi, Hodge, Lucy S. , Maurer, Matthew J. , Ziesmer, Steven C., Link, Brian K. , Cerhan, James R. , Novak, Anne J. , Ansell, Stephen M. , Marri, Preethi Reddy, Slager, Susan L. , Habermann, Thomas M. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

Clinical Cancer Research | October 19, 2013 | Volume: 19 | Issue: 24 | Pages: 6812-6819

10.1158/1078-0432.ccr-13-1879 | PMID 24141626 Get It

Abstract Purpose: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. Experimental Design: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. Results: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-α, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. Conclusions: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse. Clin Cancer Res; 19(24); 6812–9. ©2013 AACR.
The pre-treatment prevalence and types of sexual dysfunction among patients diagnosed with prostate cancer
Saitz, Theodore R. , Şerefoğlu, Ege Can , Trost, Landon , Thomas, Raju , Hellstrom, Wayne J.G.

Mayo Clinic

Andrology | October 14, 2013 | Volume: 1 | Issue: 6 | Pages: 859-863

10.1111/j.2047-2927.2013.00137.x | PMID 24127273 Get It

Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort
Leal, Alexis D. , Thompson, Carrie A. , Wang, Alice H., Vierkant, Robert A. , Ross, Julie A. , Virnig, Beth A , Cerhan, James R. , Habermann, Thomas M. , Mesa, Ruben A. , Cerhan, James R , Vierkant, Robert A

Mayo Clinic

International Journal of Cancer | October 12, 2013 | Volume: 134 | Issue: 7 | Pages: 1741-1750

10.1002/ijc.28492 | PMID 24114627 Get It

Classical myeloproliferative neoplasms (MPNs) are composed of essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF), the etiology of which is largely unknown. We investigated the role of anthropometric, medical and lifestyle factors with risk of MPN in a prospective cohort of 27,370 women aged 55–69 years at enrollment. After >250,000 person‐years of follow‐up, 257 cases of MPN were identified (172 ET, 64 PV, 21 MF). Risk factor profiles were mostly unique for the two most common types, ET and PV. ET was associated with energy balance factors including body mass index (RR = 1.52 for >29.3vs. <23.4 kg/m2;p‐trend = 0.042), physical activity (RR = 0.66 for highvs. low;p‐trend = 0.04) and adult onset diabetes (RR = 1.82;p = 0.009), while PV was not. PV was associated with current smoking (RR = 2.83;p‐trend = 0.016), while ET was not. Regular use of aspirin was associated with lower risk of ET (RR = 0.68;p = 0.017). These results broadly held in multivariate models. Our results suggest distinct etiologies for these MPN subtypes and raise mechanistic hypotheses related to obesity‐related inflammatory pathways for ET and smoking‐related carcinogenic pathways for PV. Regular aspirin use may lower risk for ET.
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
Aurora, SK, Diener, HC, DeGryse, Ronald E., Turkel, Catherine C., Silberstein, Stephen D., Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Acta Neurologica Scandinavica | October 11, 2013 | Volume: 129 | Issue: 1 | Pages: 61-70

10.1111/ane.12171 | PMID 24107267 Get It

P3–295: The Placebo Data Analysis in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) Clinical Trials Project: Overview of progress in trial data collection, and key findings from the pooled Alzheimer's disease trial datasets
Thomas, Ronald J. , Petersen, Ronald, Carrillo, Maria, Albert, Marilyn, Aisen, Paul, Initiative, Alzheimer's Disease Neuroimaging, Siuciak, Judith A. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_16 | Pages: No page available

10.1016/j.jalz.2013.05.1369 Get It